-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR ...
On Thursday, Elevation Oncology, Inc. (NASDAQ:ELEV) elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC). The company was developing a treatment for advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback